Compare NMFC & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NMFC | LXRX |
|---|---|---|
| Founded | 2010 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 796.4M | 703.3M |
| IPO Year | N/A | 2000 |
| Metric | NMFC | LXRX |
|---|---|---|
| Price | $7.94 | $2.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $8.63 | $4.15 |
| AVG Volume (30 Days) | 554.1K | ★ 2.9M |
| Earning Date | 05-04-2026 | 05-01-2026 |
| Dividend Yield | ★ 15.27% | N/A |
| EPS Growth | N/A | ★ 77.78 |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $49,803,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.51 | ★ N/A |
| Revenue Growth | N/A | ★ 60.24 |
| 52 Week Low | $7.47 | $0.62 |
| 52 Week High | $11.04 | $2.53 |
| Indicator | NMFC | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.59 | 59.11 |
| Support Level | $7.50 | $1.14 |
| Resistance Level | $8.65 | $2.53 |
| Average True Range (ATR) | 0.20 | 0.18 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 8.76 | 63.37 |
New Mountain Finance Corp is a closed-end, non-diversified management investment company. It invests in equity interests such as preferred stock, common stock, warrants, or options received in connection with debt investments or may include direct investment in the equity of private companies. The company's investment objective is to generate current income and capital appreciation through sourcing and origination of debt securities at all levels of the capital structure, including first and second-lien debt, notes, bonds and mezzanine securities.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.